Boston, MANCT00595491Now EnrollingIRB Ready

Asthma Clinical Trial in Boston, MA

Access cutting-edge asthma treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by Benjamin Medoff

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access asthma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related asthma treatment provided free

Apply for This Boston Location

Check if you qualify for this asthma clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Asthma Study in Boston

Asthma is a heterogeneous disorder in which multiple potential inflammatory pathways contribute to airway obstruction. The biological basis for airway inflammation is the subject of intensive investigation. This work is designed to identify airway factors that are responsible for recruiting cells and associate their airway presence with atopy and asthma.

Sponsor: Benjamin Medoff

Who Can Participate

Inclusion Criteria

All subjects will have a baseline FEV1 determined at the characterization visit that is no less than 75 % of the predicted value.
All subjects will have a clinical history of allergic symptoms to cat or dust mite allergen and demonstrated skin reactivity (a positive allergen prick test).
Life-long absence of cigarette smoking (defined as a lifetime total of less than 5 pack-years); none in 5 years).
Willing and able to give informed consent.
Expressed the desire to participate in an interview with the principal investigator.
Age between 18 and 50 years.

Exclusion Criteria

Women of childbearing potential who are documented to be pregnant (based on Urine beta-HCG testing), are sexually active and not using contraception, are seeking to become pregnant, or who are nursing.
The presence of spontaneous asthmatic episode or clinical evidence of upper respiratory tract infection within the previous 6 weeks.
Participation in research study involving a drug or biologic during the 30 days prior to the study.
Intolerance to albuterol, atropine, lidocaine, fentanyl, or midazolam.
Antihistamines within 7 days of the screening visit.
Presence of diabetes mellitus, congestive heart failure, ventricular arrhythmias, history of a cerebrovascular accident, renal failure, history of anaphylaxis, or cirrhosis.
Use of systemic steroids, increased use of inhaled steroids, beta blockers and MAO inhibitors or a visit for an asthma exacerbation within 1 month of the screening visit.
Antibiotic use for respiratory disease within 1 month of the characterization visit or a respiratory tract infection within 6 weeks of the bronchoscopy visits.
A history of asthma-related respiratory failure requiring intubation.
Quantitative skin-prick test positive reaction down to an allergen concentration of 0.056 BAU or AU/ml .
Taking beta-adrenergic blocking agents or monoamine oxidase inhibitors.
Subjects with a high possibility of poor compliance with the study.
No history of cigarette smoking within the past 5 years or \> 10 pack years total.
Having second-hand cigarette smoke exposure or indoor furry pets except in the case of dog, if the subject is not allergic to the dog and the subject has a negative skin test to dog (It is also preferred but not required that dust mite allergic subjects have dust mite-proof encasings on their mattress and pillows.)
Other lung diseases, such as sarcoidosis, bronchiectasis or active lung infection.
Use of Xolair (omalizumab - anti-IgE monoclonal antibody) for 6 months.
Immunotherapy with cat or dust mite extract now or in the past.
Non-English speakers.
History of coagulopathy, thrombocytopenia, pulmonary hypertension, and/or use of anti-coagulants/anti-platelet drugs. B. Healthy Normal Control Subjects (NC subjects) Normal control subjects will be individuals who are in good overall health, age and sex matched to the asthmatic group, age 18 - 50 and nonallergic, i.e. entirely negative on the panel of prick skin tests listed in section V (Study Procedures), with no history of allergic rhinitis or asthma, no history of allergic symptoms caused by cats or dust mite allergen exposure, life-long nonsmokers of cigarettes (defined as a lifetime total of less than 5 pack-years and none in 5 years), normal spirometry (i.e. FEV1 and FVC of at least 90% of predicted) and with a methacholine PC20 of \> 16 mg/ml. Exclusion Criteria:
A history of allergy, asthma, nasal or sinus disease.
ANA subjects will have a history of either (a) allergic rhinitis (with one or more of the following symptoms: nasal congestion, sneezing, runny nose, postnasal drainage), (b) allergic conjunctivitis (ocular itching, tearing and/or swelling) or (c) contact allergy associated with cat dander or dust mite and a positive allergy test to the same allergen.
All subjects will have a baseline FEV1 and FVC determined at the characterization visit that is no less than 90 % of the predicted value.
All subjects will have a positive allergy skin prick test to cat dander or dust mite allergen.
All subjects will be in good general health.
Life-long absence of cigarette smoking (defined as a lifetime total of less than 5 pack-years and none in 5 years).
Willing and able to give informed consent.
Expressed the desire to participate in an interview with the principal investigator.
Age between 18 and 50 years. Exclusion Criteria:
A history of asthma.
A methacholine PC20 \< 16 mg/ml.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT00595491) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Asthma Treatment Options in Boston, MA

If you're searching for asthma treatment options in Boston, MA, this clinical trial (NCT00595491) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced asthma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all asthma clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Boston, MA

See all ankylosing spondylitis clinical trials recruiting in Boston — not just this study.

Browse Ankylosing Spondylitis Trials in Boston

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA